BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Trial Success With Rare Disease Drug Nets Bonuses for Two BioMarin Pharmaceutical Inc. (BMRN) Execs


11/29/2012 8:11:53 AM

BioMarin Pharmaceutical Inc.'s solid Phase III trial of an experimental treatment for a rare crippling disease netted two of its executives hefty cash bonuses. Dr. Henry Fuchs, chief medical officer of the Novato company (NASDAQ: BMRN), received a $100,000 bonus, the company said Wednesday in a Securities and Exchange Commission filing. Robert Baffi, the executive vice president of technical operations, scored a $50,000 bonus. BioMarin said that its board of directors' compensation committee awarded the bonuses Monday "to reward them for their extraordinary efforts" on the late-stage trial of the drug BMS-110 for paitnets with mucopolysaccharidosis type IVA, or MPS IVA.


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->